TIRmed Pharma have begun a permeability study on their cream targeting Atopic Dermatitis, TIR-C. The study will showcase its ability to penetrate human skin – thus being a critical validation milestone. Furthermore, the study will provide data that will be used to define the concentration necessary of the active oligonucleotide TIR-01 in TIR-C. Joanneum Research, […]
Eczema is a common disease affecting up to 20% of children and approximately 3% of adults, with a drugs market estimated up to 75 BSEK worldwide. The intense itch associated with the condition can lead to sleeping disorders, anxiety and depression. There is no cure as of today. The current treatments can ameliorate the symptoms. […]
Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide Authors: Aleksandra Dondalska, Elin Rönnberg, Haisha Ma, Sandra Axberg Pålsson, Elin Magnusdottir, Tianle Gao, Lucille Adam, Ethan A. Lerner , Gunnar Nilsson, Malin Lagerström and Anna-Lena Spetz Front. Immunol., 30 September 2020 https://doi.org/10.3389/fimmu.2020.559589
TIRmed Pharma´s proprietary compound to treat inflammatory skin disorders was issued patent approval in the US, April 21st, 2020.
In Dec, 2019 TIRmed Pharma was awarded funding from the European Union´s Horizon 2020 research and innovation progamme under grant agreement number 885787-TIR-C regarding the development of a cream to treat immune responses in atopic dermatitis.